

# **Addition of intravenous beta<sub>2</sub>-agonists to inhaled beta<sub>2</sub>-agonists for acute asthma (Review)**

Travers AH, Milan SJ, Jones AP, Camargo Jr CA, Rowe BH



**THE COCHRANE  
COLLABORATION®**

This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in *The Cochrane Library* 2012, Issue 12

<http://www.thecochranelibrary.com>



---

**Addition of intravenous beta<sub>2</sub>-agonists to inhaled beta<sub>2</sub>-agonists for acute asthma (Review)**  
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

## TABLE OF CONTENTS

HEADER . . . . .	1
ABSTRACT . . . . .	1
PLAIN LANGUAGE SUMMARY . . . . .	2
SUMMARY OF FINDINGS FOR THE MAIN COMPARISON . . . . .	3
BACKGROUND . . . . .	5
OBJECTIVES . . . . .	5
METHODS . . . . .	5
RESULTS . . . . .	7
Figure 1. . . . .	8
Figure 2. . . . .	9
Figure 3. . . . .	10
DISCUSSION . . . . .	12
AUTHORS' CONCLUSIONS . . . . .	12
ACKNOWLEDGEMENTS . . . . .	13
REFERENCES . . . . .	13
CHARACTERISTICS OF STUDIES . . . . .	19
DATA AND ANALYSES . . . . .	31
Analysis 1.1. Comparison 1 IV + inhaled beta agonist vs. inhaled beta-agonist, Outcome 1 Admissions. . . . .	31
Analysis 1.2. Comparison 1 IV + inhaled beta agonist vs. inhaled beta-agonist, Outcome 2 Length of stay. . . . .	32
Analysis 1.3. Comparison 1 IV + inhaled beta agonist vs. inhaled beta-agonist, Outcome 3 Pulse rate at 2 hours. . . . .	32
Analysis 1.4. Comparison 1 IV + inhaled beta agonist vs. inhaled beta-agonist, Outcome 4 Clinical Failure. . . . .	33
APPENDICES . . . . .	33
HISTORY . . . . .	35
CONTRIBUTIONS OF AUTHORS . . . . .	35
DECLARATIONS OF INTEREST . . . . .	35
SOURCES OF SUPPORT . . . . .	36

[Intervention Review]

# Addition of intravenous beta<sub>2</sub>-agonists to inhaled beta<sub>2</sub>-agonists for acute asthma

Andrew H Travers<sup>1</sup>, Stephen J Milan<sup>2</sup>, Arthur P Jones<sup>3</sup>, Carlos A Camargo Jr<sup>4</sup>, Brian H Rowe<sup>5,6</sup>

<sup>1</sup>Department of Emergency Medicine and Community Health and Epidemiology, Emergency Health Services, Nova Scotia, Canada.

<sup>2</sup>Population Health Sciences and Education, St George's, University of London, London, UK. <sup>3</sup>c/o Cochrane Airways Group, London, UK. <sup>4</sup>Department of Emergency Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA. <sup>5</sup>Department of Emergency Medicine, University of Alberta, Edmonton, Canada. <sup>6</sup>School of Public Health, University of Alberta, Edmonton, Canada

Contact address: Andrew H Travers, Department of Emergency Medicine and Community Health and Epidemiology, Emergency Health Services, Nova Scotia, Canada. [Andrew.Travers@gov.ns.ca](mailto:Andrew.Travers@gov.ns.ca).

**Editorial group:** Cochrane Airways Group.

**Publication status and date:** New, published in Issue 12, 2012.

**Review content assessed as up-to-date:** 28 September 2012.

**Citation:** Travers AH, Milan SJ, Jones AP, Camargo Jr CA, Rowe BH. Addition of intravenous beta<sub>2</sub>-agonists to inhaled beta<sub>2</sub>-agonists for acute asthma. *Cochrane Database of Systematic Reviews* 2012, Issue 12. Art. No.: CD010179. DOI: 10.1002/14651858.CD010179.

Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

## ABSTRACT

### Background

Inhaled beta-agonist therapy is central to the management of acute asthma. This review evaluates the benefit of an additional use of intravenous beta<sub>2</sub>-agonist agents.

### Objectives

To determine the benefit of adding intravenous (IV) beta<sub>2</sub>-agonists to inhaled beta<sub>2</sub>-agonist therapy for acute asthma treated in the emergency department.

### Search methods

Randomised controlled trials (RCTs) were identified using the Cochrane Airways Group Register which is a compilation of systematic searches of MEDLINE, EMBASE, CINAHL, and CENTRAL as well as handsearching of 20 respiratory journals. Bibliographies from included studies and known reviews were also searched. Primary authors and content experts were contacted to identify eligible studies. The search was performed in September 2012.

### Selection criteria

Only RCTs were considered for inclusion. Studies were included if patients presented to the emergency department with acute asthma and were treated with IV beta<sub>2</sub>-agonists with inhaled beta<sub>2</sub>-agonist therapy and existing standard treatments versus inhaled beta<sub>2</sub>-agonists and existing standard treatments.

### Data collection and analysis

Two review authors independently extracted data and confirmed their findings with corresponding authors of trials. We obtained missing data from authors or calculated from data present in the papers. We used fixed-effect model for odds ratios (OR) and for mean differences (MD) we used both fixed-effect and random-effects models and reported 95% confidence intervals (CI).

## Main results

From 109 potentially relevant studies only three (104 patients) met our inclusion criteria: Bogie 2007 (46 children), Browne 1997 (29 children) and Nowak 2010 (29 adults). Bogie 2007 investigated the addition of intravenous terbutaline to high dose nebulised albuterol in children with acute severe asthma, requiring intensive care unit (ICU) admission. Browne 1997 investigated the benefit of adding intravenous salbutamol to inhaled salbutamol in children with acute severe asthma in the emergency department. Nowak 2010 investigated addition of IV bedoradrine to standard care (nebulised albuterol, ipratropium and oral corticosteroids) among adults, and was reported as a conference abstract only.

There was no significant advantage (OR 0.29; 95%CI 0.06 to 1.38, one trial, 29 adults) for adding IV bedoradrine to standard care (nebulised albuterol, ipratropium and oral corticosteroids) with regard to hospitalisation rates.

Various outcome indicators for the length of stay were reported among the trials. Browne 1997 reported a significantly shorter recovery time (in terms of cessation of 30 minute salbutamol) for children in the IV salbutamol with inhaled salbutamol group (four hours) versus the 11.1 hours for the inhaled salbutamol group ( $P = 0.03$ ). Time to cessation of hourly nebuliser was also significantly shorter ( $P = 0.02$ ) for the IV plus inhaled salbutamol group (11.5 hours versus 21.2 hours), and they were ready for emergency patient discharge on average 9.7 hours earlier than the inhaled salbutamol group ( $P < 0.05$ ). In a paediatric ICU study Bogie 2007 reported no significant advantage in length of paediatric ICU admission (hours) for adding IV terbutaline to nebulised albuterol (MD -12.95, 95% CI: -38.74, 12.84).

Browne 1997 reported there were only six out of 14 children with a pulmonary index score above six in the IV plus inhaled salbutamol group at two hours compared with 14 of the 15 in the inhaled salbutamol group ( $P = 0.02$ )

In Browne 1997 there was a higher proportion of tremor in the IV plus inhaled salbutamol group than in the inhaled salbutamol group ( $P < 0.02$ ). Nowak 2010 did not report any statistically significant adverse effects associated with adding IV bedoradrine to standard care (nebulised albuterol, ipratropium and oral corticosteroids). Troponin levels were elevated in three children in the IV terbutaline + nebulised albuterol group at 12 and 24 hours in Bogie 2007

## Authors' conclusions

There is very limited evidence from one study (Browne 1997) to support the use of IV beta<sub>2</sub>-agonists in children with severe acute asthma with respect to shorter recovery time, and similarly there is limited evidence (again from one study Browne 1997) suggesting benefit with regard to pulmonary index scores; however this advantage needs to be considered carefully in relation to the increased side effects associated with IV beta<sub>2</sub>-agonists. We identified no significant benefits for adults with severe acute asthma. Until more, adequately powered, high quality clinical trials in this area are conducted it is not possible to form a robust evaluation of the addition of IV beta<sub>2</sub>-agonists in children or adults with severe acute asthma.

## PLAIN LANGUAGE SUMMARY

### Addition of intravenous beta<sub>2</sub>-agonists to inhaled beta<sub>2</sub>-agonists for acute asthma

Beta<sub>2</sub>-agonist drugs are used for the treatment of asthma and work by opening the airways to help people breathe more easily. Beta<sub>2</sub>-agonists can be given to people in two different ways - intravenously (directly thorough a vein) and via an inhaler. Inhalers are one of the most important treatments for people with acute severe asthma. The question this review considered was whether treatment would offer additional benefit if patients received these drugs both ways (by breathing them via an inhaler and receiving them directly through a vein) than by just inhaling them alone. This review examined all the randomised controlled trials on the use of intravenous beta<sub>2</sub>-agonists in addition to inhaled beta<sub>2</sub>-agonists with existing standard care (such as steroids either taken as tablets or by injection) in severe acute asthma.

We found three trials involving 104 people (75 children and 29 adults) with acute asthma. There was no significant difference in adults receiving intravenous beta-agonists as well as standard care in the one small trial considering this comparison. We also looked at length of stay in the emergency department. Two reported shorter recovery time or quicker discharge from the emergency department in patients also receiving intravenous beta-agonists. One trial reported that more children experienced tremor if they had received injected beta-agonists whereas another trial, with adults, reported no significant difference in adverse effects. As there are so few trials and so few included patients we cannot be sure about the reliability of these findings.

This review found that until more, larger, high quality clinical trials in this area are conducted it is not possible to judge whether there is any enhanced benefit using additional intravenous beta<sub>2</sub>-agonists in children or adults with severe acute asthma compared with inhaled beta<sub>2</sub>-agonists alone.

## SUMMARY OF FINDINGS FOR THE MAIN COMPARISON *[Explanation]*

IV + inhaled beta agonist compared to inhaled beta-agonist for acute asthma						
<b>Patient or population:</b> patients with acute asthma <b>Settings:</b> ED and ICU <b>Intervention:</b> IV + inhaled beta agonist <b>Comparison:</b> inhaled beta-agonist						
Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	inhaled beta-agonist	IV + inhaled beta agonist				
<b>Admissions to hospital</b>	<b>54 per 100</b>	<b>25 per 100</b> (7 to 62)	<b>OR 0.29</b> (0.06 to 1.38)	29 (1 study)	⊕⊕○○ <b>low</b> <sup>1</sup>	
<b>Length of stay in emergency department</b>	mean control group stay was 57 (SD 56) minutes	The mean length of stay in the intervention groups was <b>12.95 minutes lower</b> (38.74 lower to 12.84 higher)	MD -12.95 (-38.74 to 12.84)	46 (1 study)	⊕⊕⊕○ <b>moderate</b> <sup>2</sup>	
<b>Pulse rate at 2 hours</b>	the mean heart rate in the control group was 142 (SD 10)	The mean heart rate at 2 hours in the intervention groups was <b>10 beats per minute higher</b> (1.07 lower to 21.07 higher)	MD 10.00 (-1.07 to 21.07)	29 (1 study)	⊕⊕⊕○ <b>moderate</b> <sup>2</sup>	

<b>Clinical Failure</b> (children with a severe to moderate overall clinical assessment score at two hours)	<b>93 per 100</b>	<b>56 per 100</b> (22 to 84)	<b>OR 0.09</b> (0.02 to 0.38)	29 (1 study)	⊕⊕⊕○ <b>moderate</b> <sup>2</sup>
--	-------------------	---------------------------------	----------------------------------	-----------------	--------------------------------------

\*The basis for the **assumed risk** (e.g. the median control group risk across studies) is provided in footnotes. The **corresponding risk** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).

**CI:** Confidence interval; **OR:** Odds ratio;

GRADE Working Group grades of evidence

**High quality:** Further research is very unlikely to change our confidence in the estimate of effect.

**Moderate quality:** Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.

**Low quality:** Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

**Very low quality:** We are very uncertain about the estimate.

<sup>1</sup> Admissions: one point deducted for risk of bias due to lack of clarity in randomisation and blinding procedures, and an additional point deducted as data contributed by only one study

<sup>2</sup> An additional point deducted as data contributed by only one study

## BACKGROUND

### Description of the condition

In the period 2005 to 2006 there were 65,732 hospital admissions for asthma in the UK (NHS 2011), and 10 million people experience asthma exacerbations in the US each year (Krishnan 2006). Approximately 10% to 20% of acute asthma cases in the US lead to hospital admission, and a similar proportion of those discharged from the emergency department relapse within the following 14 days (Emerman 1999; Emerman 2001). Over the last two decades several national (e.g. Boulet 1999; BTS 1997; BTS/SIGN 2011; NAEPP 1997; NIH 2007) and international (e.g. GINA 2011; NHLBI/WHO 1995) guidelines have been produced for the management of acute asthma.

### Description of the intervention

Over the last 25 years there have been numerous examples of studies investigating the role of IV beta<sub>2</sub>-agonists in the management of acute asthma. In North America and Europe practice guidelines have recommended inhaled beta<sub>2</sub>-agonist therapy for all emergency department management of asthma (Beveridge 1996; BTS/SIGN 2011; Ernst 1996; GINA 2011; Lipworth 1997; NAEPP 1997; NIH 2007).

### How the intervention might work

The conventional and recommended management of severe acute asthma is to use beta<sub>2</sub>-agonist bronchodilators and corticosteroids. When aiming to ensure efficient bronchodilatation, especially in severe acute asthma, penetration of an inhaled drug to the affected small conducting airways may be limited, and positive reactions may be a result of the drug reaching the receptors via the systemic circulation. In these circumstances, if bronchodilatation occurs predominantly in response to the systemic distribution of the drug, intravenous (IV) in addition to inhaled administration of bronchodilators may provide an earlier clinical response (Browne 1997).

### Why it is important to do this review

For patients unresponsive to inhaled bronchodilator and systemic corticosteroid therapy IV beta<sub>2</sub>-agonists are considered as second line therapy. Alternatively they are considered if the inhaled route is not practical for the patient (Beveridge 1996; BTS/SIGN 2011; Ernst 1996; GINA 2011; Lipworth 1997; NAEPP 1997; NIH 2007). However, the benefit of this route of delivery remains a matter of intense debate. The previous systematic review by Travers (Travers 2001), concluded that 'There is no evidence to support the use of IV beta<sub>2</sub>-agonists in patients with severe acute asthma.

These drugs should be given by inhalation. No subgroups were identified in which the IV route should be considered.' This is a new review based on the previous protocol for Travers 2001. The review aims to evaluate that conclusion with regard to relevant randomised controlled trials published over the last 11 years investigating the addition of intravenous beta agonists to inhaled beta agonist therapy.

A separate review is available on *The Cochrane Library* for 'Continuous versus intermittent beta<sub>2</sub>-agonists for acute asthma' (Camargo 2011) and reviews of epinephrine for acute asthma and intravenous beta<sub>2</sub>-agonists versus intravenous aminophylline are currently in preparation.

## OBJECTIVES

To determine if the evidence from randomised trials supports the use of IV beta<sub>2</sub>-agonists in addition to inhaled beta<sub>2</sub>-agonists in the treatment of patients with severe acute asthma who present to the emergency department.

## METHODS

### Criteria for considering studies for this review

#### Types of studies

We included randomised controlled trials (RCTs).

#### Types of participants

We included studies of adult or paediatric patients with severe acute asthma presenting to an emergency room (or its equivalent).

#### Types of interventions

The target intervention was the administration of IV selective or non-selective beta<sub>1</sub> and beta<sub>2</sub>-agonists.

We compared IV beta<sub>2</sub>-agonists used in addition to inhaled beta<sub>2</sub>-agonists and existing standards of care with inhaled beta<sub>2</sub>-agonists and standard care alone.

#### Types of outcome measures

##### Primary outcomes

1. Hospital admission
2. Length of stay

## Secondary outcomes

1. Pulmonary function
2. Vital signs
3. Adverse effects
4. Clinical scores

## Search methods for identification of studies

### Electronic searches

We identified trials from the Cochrane Airways Group Specialised Register of trials (CAGR), which is derived from systematic searches of bibliographic databases including the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, CINAHL, AMED, and PsycINFO and handsearching of respiratory journals and meeting abstracts (please see [Appendix 1](#) for further details). We searched records in the CAGR coded as 'asthma' using the terms given in [Appendix 2](#). We also conducted a search of ClinicalTrials.gov and the search strategy is given in [Appendix 2](#). All databases were searched from their inception to the present and there was no restriction on language of publication. The searches were conducted in November 2011 and updated in September 2012.

### Searching other resources

Enquiries regarding other published or unpublished studies known and/or supported by the authors of the primary studies were made so that these results could be included in this review. Several pathways were used to locate authors including letters to an address presented in the article, Internet 'People and Hospital Searches', electronic author searches in library databases for the address on the most recent article published by the author, and contact with other review authors in the Cochrane Airways Group. Scientific advisors of the various pharmaceutical companies (Glaxo) that manufacture beta<sub>2</sub>-agonists were contacted for any unpublished, published, or interim results on beta<sub>2</sub>-agonist research. Personal contact with colleagues, collaborators and other trialists working in the field of asthma was made to identify potentially relevant studies. We searched reference lists of included papers and other systematic reviews for additional relevant studies.

## Data collection and analysis

### Selection of studies

The reference lists from the search strategy was independently reviewed by two review authors (AHT, SJM), and clearly irrelevant articles were discarded. If the title, abstract, or descriptors suggested any potential relevance, the full text article was retrieved.

Two review authors (SJM, AHT) then assessed each relevant paper for inclusion in this review. The review authors were not blinded to the authors, journal of publication, or results of the studies as investigator bias was deemed unlikely. Disagreement would have been resolved by consensus or third party adjudication (CC).

### Data extraction and management

Two review authors (AHT, SJM) independently extracted data and one review author (SJM) entered the data into The Cochrane Collaboration software program (Review Manager Version 5.1 [Revman 2011](#)).

### Assessment of risk of bias in included studies

The risk of bias of included studies was assessed using the Collaboration's risk of bias methodology see Chapter 8 of the *Cochrane Handbook of Systematic Reviews of Interventions* ([Higgins 2011](#)). Two review authors (AHT and SJM) assessed the risk of bias for all included studies with regard to random sequence generation, allocation concealment, blinding, incomplete outcome data and selective outcome reporting. Each item was assessed as high, low or unclear risk of bias along with relevant information reported in the randomised controlled trial.

### Measures of treatment effect

For dichotomous variables, data are expressed as odds ratios (OR) with 95% confidence intervals (CI). Data for continuous variables were reported as mean differences (MD) with 95% CIs.

### Unit of analysis issues

The unit of analysis was the patient.

### Dealing with missing data

We planned to contact authors if outcome data or information on trial design was missing; however, this need did not arise.

### Assessment of heterogeneity

Heterogeneity was assessed with regard to the forest plots. The Chi<sup>2</sup> test was similarly considered (P value < 0.10) but interpreted with caution owing to the low power associated with this test. I<sup>2</sup> ([Higgins 2011](#)) was also considered and interpreted in relation to the following guidance:

- 0% to 40%: might not be important;
- 30% to 60%: may represent moderate heterogeneity;
- 50% to 90%: may represent substantial heterogeneity; and
- 75% to 100%: considerable heterogeneity ([Higgins 2011](#)).



### Assessment of reporting biases

Examination of publication bias was planned, using funnel plots, if there was an adequate number of trials aggregated in the analyses. It is however recognised that an asymmetrical funnel plot can reflect heterogeneity, outcome reporting bias and small study effects and is therefore, not necessarily a reflection of publication bias, especially in reviews of less than 10 trials..

### Data synthesis

We planned to combine data using the Review Manager 5.1 software ([Revman 2011](#)), however we were unable to pool any data. For continuous variables, a random-effects MD and 95% CI were calculated for each study. For dichotomous variables, a random-effects OR with 95% CI was calculated for individual studies. All similar studies were pooled using random-effects OR or MD and 95% CIs.

### Subgroup analysis and investigation of heterogeneity

The following subgroup analysis was planned; however, the small number of available trials did not make this possible.

- Population: adult versus paediatric

### Sensitivity analysis

Sensitivity analyses were planned but the paucity of data meeting the inclusion criteria for the review precluded us from conducting this assessment.

## RESULTS


### Description of studies

See: [Characteristics of included studies](#); [Characteristics of excluded studies](#).

### Results of the search

The Cochrane Airways Group database searches identified a total of 425 references, and an additional 49 references were identified from [Travers 2001](#). Independent review of the abstracts and titles of these publications identified three studies assessed as eligible for inclusion in the review ([Figure 1](#)).

**Figure 1. Study flow diagram.**



### Included studies

Three studies on 104 people met our inclusion criteria [Bogie 2007](#) (46 children), [Browne 1997](#) (29 children) and [Nowak 2010](#) (29 adults). [Bogie 2007](#) and [Browne 1997](#) were paediatric studies of severe acute asthma, but differed in the clinical setting. [Bogie 2007](#) investigated the benefit of adding intravenous terbutaline to high-dose nebulised albuterol in children with acute severe asthma who required intensive care unit (ICU) admission. [Browne 1997](#) investigated the benefit of adding intravenous salbutamol to inhaled salbutamol in children with acute severe asthma in the emergency department (ED).

[Nowak 2010](#) is reported as a conference abstract and the information available is relatively limited. The objective was to assess the benefit of adding IV bedoradrine to standard care (nebulised albuterol, ipratropium and oral corticosteroids) in the treatment of severe acute exacerbations of asthma.

### Excluded studies

One hundred and six studies failed to meet the eligibility criteria of this review. Forty (38%) were not randomised and in 22 (21%) the focus was on epinephrine (rather than IV beta<sub>2</sub>-agonists). Thirteen (12%) trials assessed inhaled beta<sub>2</sub> agonists versus IV beta<sub>2</sub> agonists and 11 (10%) compared IV beta<sub>2</sub> agonists versus IV methylxanthines. In a further five studies (5%) the focus was

on subcutaneous (rather than IV) beta<sub>2</sub> agonists and in three (3%) trials the patients has chronic asthma rather than acute asthma. A further two (2%) were reviews and two (2%) trials compared IV beta<sub>2</sub> agonists versus nebulised ipratropium. Another two (2%) were excluded as they were conducted in a laboratory setting rather than in the emergency department. The remaining six were excluded because one (1%) trial compared IV terbutaline versus IV prenalterol, one (1%) trial compared beta<sub>2</sub> agonists against steroids, another (1%) trial compared two IV beta<sub>2</sub> agonists, and another (1%) trial compared ipratropium plus standard care versus standard care alone. One (1%) trial compared IV beta<sub>2</sub> agonists versus IV atrial natriuretic factor (ANF) and another (1%) trial compared IV salbutamol versus IV epinephrine. The reasons for the exclusion of each reference is given in [Characteristics of excluded studies](#).

### Risk of bias in included studies

#### Allocation

Two studies were judged to be at low risk of selection bias ([Bogie 2007](#); [Browne 1997](#)) and in the third (reported as a conference abstract) it was unclear ([Nowak 2010](#)). Full details of our 'Risk of bias' judgements can be found in [Characteristics of included studies](#) and the judgements are presented graphically in [Figure 2](#) and [Figure 3](#).

**Figure 2. 'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.**




Figure 3. 'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study.

	Random sequence generation (selection bias)	Allocation concealment (selection bias)	Blinding of participants and personnel (performance bias)	Blinding of outcome assessment (detection bias)	Incomplete outcome data (attrition bias)	Selective reporting (reporting bias)
Bogie 2007	+	+	+	+	+	?
Browne 1997	+	+	+	+	+	?
Nowak 2010	?	?	?	?	?	?

### Blinding

Two of the included studies were assessed as low risk of bias (Bogie 2007; Browne 1997) and in (Nowak 2010) the risk was assessed as unclear.

### Incomplete outcome data

Two of the included studies were judged to be at low risk of attrition bias (Bogie 2007; Browne 1997) and in the third the risk was judged to be unclear (Nowak 2010).

### Selective reporting

In all three studies the risk of reporting bias was assessed as unclear.

### Effects of interventions

See: [Summary of findings for the main comparison IV + inhaled beta agonist compared with inhaled beta-agonist for acute asthma](#)  
Very little data from the three included studies were reported in a form that could be incorporated in meta-analyses.

### Admissions

One study (Nowak 2010) with 29 adult patients indicates there was no significant advantage for adding IV bedoradrine to standard care (nebulised albuterol, ipratropium plus oral corticosteroids) with regard to hospitalisation rates (OR 0.29; 95% CI 0.06 to 1.38; [Analysis 1.1](#)).

### Length of stay

(Browne 1997) reported a significantly shorter recovery time (in terms of cessation of 30 minute salbutamol) for children in the IV plus inhaled salbutamol group (four hours) versus 11.1 hours for the inhaled salbutamol group ( $P = 0.03$ ). Time to cessation of hourly nebuliser was also significantly shorter ( $P = 0.02$ ) for the IV plus inhaled salbutamol group (11.5 hours versus 21.2 hours), and they were ready for emergency patient discharge on average 9.7 hours earlier than the inhaled salbutamol group ( $P < 0.05$ ). In a paediatric ICU study, (Bogie 2007) reported no significant advantage in length of PICU admission (hours) for adding IV terbutaline to nebulised albuterol (mean difference (MD) -12.95; 95% CI -38.74 to 12.84; [Analysis 1.2](#)).

### Heart rate

There was no significant difference in heart rates for paediatric patients between the IV plus inhaled salbutamol and inhaled salbutamol groups at two hours (one study, 29 participants; [Analysis 1.3](#)).

### Need for supplemental oxygen

In (Browne 1997) only two of the 14 children in the IV plus inhaled salbutamol group were on medical oxygen at two hours, contrasting with eight of the 15 in the inhaled salbutamol group ( $P = 0.05$ ).

### Asthma severity score

A study in 46 children in ICU (Bogie 2007) reported a significant benefit in adding IV terbutaline to nebulised albuterol in relation to the improvement of Clinical Asthma Severity Scores over the first 24 hours of 6.5 points in the IV plus inhaled group compared with 4.8 points in inhaled group ( $P = 0.073$ ). In another paediatric study, (Browne 1997) reported a significant benefit of adding IV salbutamol to nebulised salbutamol in relation to the improvement in both the National Australian Asthma Campaign Severity clinical assessment scale and the pulmonary index score. The National Australian Asthma Campaign Severity clinical assessment scale was measured at two hours where (36% (5/14) had persistent moderate to severe asthma in the IV plus inhaled salbutamol group compared with 93% (14/15) in the inhaled salbutamol only group ( $P < 0.002$ ); these data are included in [Analysis 1.4](#) as a measure of clinical failure, and in view of the small number of participants in this single study should be interpreted with caution. The pulmonary index score was  $\geq$  seven at two hours in six out of 14 (43%) participants in the IV plus inhaled salbutamol group versus 13 out of 15 (93%) in the inhaled salbutamol only group ( $P < 0.02$ ).

### Adverse effects

Although we were unable to pool data, all three studies reported information on adverse effects. In (Browne 1997) there was a higher proportion of tremor in the IV plus inhaled salbutamol group than in the inhaled salbutamol group ( $P < 0.02$ ). (Nowak 2010) did not report any statistically significant adverse effects associated with adding IV bedoradrine to standard care (nebulised albuterol, ipratropium and oral corticosteroids). Troponin levels were elevated in three children in the IV terbutaline + nebulised albuterol group at 12 and 24 hours in (Bogie 2007).

## DISCUSSION

### Summary of main results

The randomised controlled trial literature is very limited regarding the addition of intravenous beta<sub>2</sub>-agonists to inhaled beta<sub>2</sub>-agonists in the treatment of acute asthma, and we were able to include only three small trials in this review. The two paediatric trials (Browne 1997; Bogie 2007) were generally judged to be at low risk of bias, whereas there were more uncertainties in methodological rigour and other risks of bias due to the study being published in abstract form only and with insufficient information to draw firm conclusions in the adult study (Nowak 2010).

In terms of recovery time, there is only very limited evidence from one study (Browne 1997) to support the use of IV beta<sub>2</sub>-agonists in children with severe acute asthma, and there is also very limited evidence (again from a single study Browne 1997) indicating benefit with regard to pulmonary index scores; however this advantage needs to be considered carefully in relation to the increased side effects associated with IV beta<sub>2</sub>-agonists (Browne 1997). Moreover, these positive results were reported for secondary outcomes, which are less likely to be clinically important outcomes to either patients or physicians. We identified no apparent benefits for adults with severe acute asthma from the one available study broadly meeting our inclusion criteria (Nowak 2010). A conservative interpretation of these findings is appropriate and final conclusions should be reserved until more, adequately powered, high quality clinical trials are available. On the basis of the data currently available meeting our inclusion criteria, it is not possible to form a robust evaluation of the addition of IV beta<sub>2</sub>-agonists to inhaled beta<sub>2</sub>-agonists in children or adults with severe acute asthma.

### Overall completeness and applicability of evidence

In view of the limited number of trials and patients included in this review, and the lack of opportunity for statistical aggregation, no firm conclusions can be made. The completeness and applicability of the evidence available from randomised controlled trials indicates that we should be cautious in generalising from the data. There is slightly more information available from the included studies with regard to children with severe acute asthma from the Bogie 2007 and Browne 1997 trials; however, only the latter was conducted in the emergency department. The paucity of data relating to the addition of IV beta<sub>2</sub>-agonists to inhaled beta<sub>2</sub>-agonists for adults with severe acute asthma is striking and the only available randomised study (Nowak 2010), with 29 patients, is reported in conference proceedings.

### Quality of the evidence

With regard to random sequence generation only two trials were judged to be low in risk of selection bias (Bogie 2007; Browne 1997); the risk of bias for Nowak 2010 was judged as unclear as details of the random sequence generation were not described in the trial report. In terms of the blinding of participants and personnel, Bogie 2007 and Browne 1997 were judged to be at low risk of performance and detection bias, and Nowak 2010 was assessed as unclear. Two of the included studies were judged to be at low risk of attrition bias (Bogie 2007; Browne 1997) and in the third trial, the risk was judged to be unclear Nowak 2010.

### Potential biases in the review process

The support provided by the Cochrane Airways Group in the identification of potentially relevant trials is of a very high order; however, there is inevitably a concern regarding study selection bias or publication bias in this review. There is a concern that failure to identify unpublished trials may lead to an incomplete estimation of the effects IV beta<sub>2</sub>-agonists may have when given in addition to inhaled beta<sub>2</sub>-agonists in the treatment of acute severe asthma. Having said that, an exhaustive search of the published literature, without language restrictions, for potentially relevant clinical trials was undertaken using a systematic search strategy to minimise the likelihood of bias; however, we recognize that additional unidentified trials may exist. The standardisation of reporting would improve the opportunities to draw comparisons among trials. It is also of concern that the assessment of adverse effects was hampered by a lack of standardised reporting.

### Agreements and disagreements with other studies or reviews

The earlier review (Travers 2001) included an additional comparison of inhaled beta<sub>2</sub>-agonists versus IV beta<sub>2</sub>-agonists, together with an evaluation of IV aminophylline versus IV beta<sub>2</sub>-agonists. With regard to this particular comparison there is consistency with Travers 2001 in as much as the opportunity to draw robust conclusions of the effects IV beta<sub>2</sub>-agonists may have when given in addition to inhaled beta<sub>2</sub>-agonists is limited by paucity of data and a lack of standardisation in reporting outcomes.

## AUTHORS' CONCLUSIONS

### Implications for practice

The current evidence is insufficient to provide recommendations regarding the addition of IV beta<sub>2</sub>-agonists to inhaled beta<sub>2</sub>-agonists as a standard treatment for severe acute asthma. The clinical

benefits and adverse effects that IV beta<sub>2</sub>-agonists may have when given in addition to inhaled beta<sub>2</sub>-agonists in the paediatric and adult population remains unclear since too few clinical trials were available.

## Implications for research

### Population

The clinical benefits and adverse effects that IV beta<sub>2</sub>-agonists may have when given in addition to inhaled beta<sub>2</sub>-agonists in patients with severe acute asthma needs to be clarified in adequately powered, high quality randomised trials.

### Interventions

1. Further research is required to clarify whether IV beta<sub>2</sub>-agonists improve outcomes when given in addition to nebulised bronchodilator (beta<sub>2</sub>-agonists and anticholinergics) and systemic corticosteroid therapy.

2. The evidence for subcutaneous routes of beta<sub>2</sub>-agonists (both selective and non-selective) must be formally evaluated via a systematic review.

### Outcomes

*Future research on acute asthma must concentrate on well defined outcomes which may lead to more informative overviews in the future. More specifically the following areas must be refined:*

1. Statistical planning and sample size calculations must be more carefully considered. Trials should be large enough to protect against type II error, and when multiple statistical tests are performed the increased risk of type I error should be addressed.

2. Standardisation and complete reporting of clinically relevant outcomes such as: admission to hospital, admission to intensive care department, length of hospital stay, relapse rates.

3. Complete reporting of pulmonary function tests (PFT) data in a systematic and standardised fashion would assist in further work (i.e. reporting of % predicted peak expiratory flow rate (PEFR) and changes in % predicted PEFR).

4. The inherent variability of these PFTs, particularly in acute asthma, emphasizes the need for further research into alternative measures, particularly assessment of factors that are important to the patient.

5. Standardisation and complete reporting of Asthma Severity Scores.

6. Standardisation and complete reporting of adverse reactions and side effects.

## ACKNOWLEDGEMENTS

We would particularly like to acknowledge the excellent support and assistance from Emma Welsh, Liz Stovold, and Emma Jackson of the Cochrane Airways Review group, together with the greatly appreciated guidance from Chris Cates (Cochrane Airways Review Group Co-ordinating Editor). We are most grateful to Karen Kelly and Samantha Barker for their assistance with data extraction, entry and review at an early stage of this review's development, and we are particularly grateful to Toby Lasserson, Luis Nannini and Taixiang Wu for their help with the translation of potentially relevant non-English trials. The support provided by librarians Judith Scammel, Jane Appleton and Hilary Garrett at St George's University of London is also greatly appreciated.

## REFERENCES

### References to studies included in this review

#### Bogie 2007 *{published data only}*

Bogie AL, Towne D, Luckett PM, Abramo TJ, Wiebe RA. Comparison of intravenous terbutaline versus normal saline in pediatric patients on continuous high-dose nebulized albuterol for status asthmaticus. *Pediatric Emergency Care* 2007; Vol. 23:355–61.

#### Browne 1997 *{published data only}*

Browne GJ, Penna AS, Phung X, Soo M. Randomised trial of intravenous salbutamol in early management of acute asthma in children. *Lancet* 1997;**349**:301–5.

#### Nowak 2010 *{published data only}*

Nowak R, Iwaki Y, Matsuda K, Johnson K, Dunton AW. Reduced hospital admission and improved pulmonary function following intravenous mn-221 (bedoradrine), a novel, highly selective  $\beta$ 2-adrenergic receptor agonist, adjunctive to standard of care in severe acute exacerbation of asthma [Abstract]. *Chest* 2010; Vol. 138, issue 4:166A.

### References to studies excluded from this review

#### Abd 1989 *{published data only}*

Abd El-Moneim MA, Hanafy HM, Gomaa K, Hussein MG. Comparison of inhaled salbutamol, inhaled reproterol and injected epinephrine in the treatment of acute asthma

- in children. *Alexandria Journal of Pediatrics* 1989 ;3(2): 153–60.
- Aggarwal 1986** *{published data only}*  
Aggarwal P, Pande JN, Guleria JS. Bronchodilators in acute bronchial asthma : a comparative study. *Indian Journal of Chest Diseases and Allied Sciences* 1986; Vol. 28, issue 1: 21–7.
- Anonymous 1978** *{published data only}*  
Anonymous. Intravenous versus inhaled salbutamol. *Lancet* 1978;1:80.
- Appel 1989** *{published data only}*  
Appel D, Karpel JP, Sherman M. Epinephrine improves expiratory flow rates in patients with asthma who do not respond to inhaled metaproterenol sulfate. *Journal of Allergy & Clinical Immunology* 1989;84(1):90–8.
- Arnaud 1977** *{published data only}*  
Arnaud A, Dugue P, Orehek J, Pommier de Santi P, Vervloet D, Charpin J. Treatment of acute asthma. Comparison of the effectiveness of corticosteroids and a combination of corticosteroids and an adrenergic beta-stimulant. *Nouvelle Presse Medicale* 1977;6(45):4183–6.
- Arnaud 1982** *{published data only}*  
Arnaud A, Charpin J. Interaction between corticosteroids and beta 2-agonists in acute asthma. *European Journal of Respiratory Diseases* 1982; Vol. 122 Suppl:126–31.
- Badatcheff 1989** *{published data only}*  
Badatcheff A, Person C, Raoult J, Meslier N, Racineux JL. Effects of salbutamol and intravenous adrenaline in severe asthmatic crisis. *Revue des Maladies Respiratoires* 1989; Vol. 6, issue Suppl 3:R168.
- Baur 1988** *{published data only}*  
Baur X. Treatment of severe bronchial asthma and status asthmaticus with intravenous fenoterol. *Deutsche Medizinische Wochenschrift* 1988; Vol. 113:763–6.
- Becker 1983** *{published data only}*  
Becker AB, Nelson NA, Simons FE. Inhaled salbutamol albuterol vs injected epinephrine in the treatment of acute asthma in children. *Journal of Pediatrics* 1983;102(3): 465–9.
- Ben-Zvi 1980** *{published data only}*  
Ben-Zvi Z, Lam C, Kattan M, et al. Emergency room assessment and treatment of asthma: Aerosol vs. injection. *Pediatric Research* 1980; Vol. 14, issue 4 II:No. 1280.
- Ben-Zvi 1982** *{published data only}*  
Ben-Zvi Z, Lam C, Hoffman J, Teets-Grimm KC, Kattan M. An evaluation of the initial treatment of acute asthma. *Pediatrics* 1982;70(3):348–53.
- Ben-Zvi 1983** *{published data only}*  
Ben-Zvi Z, Lam C, Spohn WA, Gribetz I, Mulvihill MN, Kattan M. An evaluation of repeated injections of epinephrine for the initial treatment of acute asthma. *American Review of Respiratory Disease* 1983;127(1):101–5.
- Beswick 1975** *{published data only}*  
Beswick K, Davies J, Davey AJ. A comparison of intravenous aminophylline and salbutamol in the treatment of severe bronchospasm. *The Practitioner* 1975;214:561–6.
- Bloomfield 1979** *{published data only}*  
Bloomfield P, Carmichael J, Petrie GR, Jewell NP, Crompton GK. Comparison of salbutamol given intravenously and by intermittent positive-pressure breathing in life-threatening asthma. *British Medical Journal* 1979;1:848–50.
- Blumenthal 1979** *{published data only}*  
Blumenthal I, Tormey W. Comparison of IV salbutamol with IV aminophylline in severe acute asthma. *Archives of Disease in Childhood* 1979;54:983–7.
- Boe 1985** *{published data only}*  
Boe J, Carlsson LG, Hetta L, Karlson B, Ljungholm K. Acute asthma - plasma levels and effect of terbutaline i.v. injection. *European Journal of Respiratory Diseases* 1985;67: 261–8.
- Bohn 1984** *{published data only}*  
Bohn D, Kalloghlian A, Jenkins J, Edmonds J, Barker G. Intravenous salbutamol in the treatment of status asthmaticus in children. *Critical Care Medicine* 1984;12: 892–6.
- Brandstetter 1980** *{published data only}*  
Brandstetter RD, Gotz VP, Mar DD. Optimal dosing of epinephrine in acute asthma . *American Journal of Hospital Pharmacy* 1980;37(10):1326–9.
- Browne 2002** *{published data only}*  
Browne GJ, Trieu L, Van Asperen P. Randomized, double-blind, placebo-controlled trial of intravenous salbutamol and nebulized ipratropium bromide in early management of severe acute asthma in children presenting to an emergency department. *Critical Care Medicine* 2002;30(2):448–53.
- Bruguerolle 1991** *{published data only}*  
Bruguerolle B, Philip-Joet F, Lagier F, Pierson F, Reynaud M, Leonardelli M, et al. Unequal day-night terbutaline IV dosing in acute severe asthma: effect on nocturnal patency, heart rate, and arterial pressure. *Chronobiology International* 1991;8(3):194–202.
- Chanez 1990** *{published data only}*  
Chanez P, Mann C, Bousquet J, Chabrier PE, Godard P, Braquet P, et al. Atrial natriuretic factor ANF is a potent bronchodilator in asthma. *Journal of Allergy & Clinical Immunology* 1990; Vol. 86, issue 3 pt 1:321–4.
- Cheong 1988** *{published data only}*  
Cheong B, Reynolds SR, Rajan G, Ward MJ. Intravenous B-agonist in severe acute asthma. *BMJ* 1988;297:448–50.
- Chiang 2000** *{published data only}*  
Chiang VW, Burns JP, Rifai N, Lipshultz SE, Adams MJ, Weiner DL. Cardiac toxicity of intravenous terbutaline for the treatment of severe asthma in children: a prospective assessment. *Journal of Pediatrics* 2000; Vol. 137, issue 1: 73–7.
- Claybo 1985** *{published data only}*  
Claybo R. Intravenous vs. nebulized salbutamol for treatment of severe status asthmaticus. *Critical Care Medicine* 1985; Vol. 13, issue 8:696–7.



- Crompton 1990** *{published data only}*  
Crompton G. Nebulized or intravenous beta-adrenoceptor agonist therapy in acute asthma. *European Respiratory Journal* 1990;**3**:125–6.
- Davis 1977** *{published data only}*  
Davis WJ, Pang LM, Chernack WJ, Mellins RB. Terbutaline in the treatment of acute asthma in childhood. *Chest* 1977; Vol. 72, issue 5:614–7.
- Downes 1973** *{published data only}*  
Downes J, Wood D, Harwood I. Intravenous isoproterenol infusion in children with severe hypercapnia due to status asthmaticus. *Critical Care Medicine* 1973;**1**(2):63–8.
- Edmunds 1981** *{published data only}*  
Edmunds AT, Godfrey S. Cardiovascular response during severe acute asthma and its treatment in children. *Thorax* 1981;**36**:534–40.
- Elenbaas 1985** *{published data only}*  
Elenbaas RM, Frost GL, Robinson WA, Collier RE, McNabney WK, Ryan JL, et al. Subcutaneous epinephrine vs. nebulized metaproterenol in acute asthma. *Drug Intelligence & Clinical Pharmacy* 1985;**19**(17-8):567–71.
- Evans 1979** *{published data only}*  
Evans WV, Monie RDH. Aminophylline, salbutamol and combined intravenous infusions in acute severe asthma [abstract]. *British Journal of Diseases of the Chest* 1979; Vol. 73:423–4.
- Evans 1980** *{published data only}*  
Evans WV, Monie J, Crimmins J, Seaton A. Aminophylline, salbutamol and combined intravenous infusions in acute severe asthma. *British Journal of Diseases of the Chest* 1980; **74**:385–9.
- Fanta 1986** *{published data only}*  
Fanta CH, Rossing TH, McFadden ER, Jr. Treatment of acute asthma. Is combination therapy with sympathomimetics and methylxanthines indicated?. *American Journal of Medicine* 1986; Vol. 80, issue 1:5–10.
- Femi-Pearse 1977** *{published data only}*  
Femi-Pearse D, George WO, Ilechukwu ST, Elegbeleye OO, Afonja AO. Comparison of intravenous aminophylline and salbutamol in severe asthma. *British Medical Journal* 1977;**1**:491.
- Fitchett 1975** *{published data only}*  
Fitchett DH, McNicol MW, Riordan JF. Intravenous salbutamol in management of status asthmaticus. *British Medical Journal* 1975;**1**:53–5.
- Gotz 1981** *{published data only}*  
Gotz VP, Brandstetter RD, Mar DD. Bronchodilatory effect of subcutaneous epinephrine in acute asthma. *Annals of Emergency Medicine* 1981; Vol. 10, issue 10:518–20.
- Grant 1976** *{published data only}*  
Grant I. Effect of intravenous injection of salbutamol in asthma. *British Journal of Clinical Pharmacology* 1976;**3**: 509–10.
- Greefhorst 1983** *{published data only}*  
Greefhorst AP, van Herwaarden CL. Ventilatory and haemodynamic effects of prenalterol and terbutaline in asthmatic patients. *European Journal of Clinical Pharmacology* 1983; Vol. 24, issue 2:173–8.
- Greif 1985** *{published data only}*  
Greif J, Markovitz L, Topilsky M. Comparison of intravenous salbutamol (albuterol) and aminophylline in the treatment of acute asthmatic attacks. *Annals of Allergy* 1985;**55**:504–6.
- Hambleton 1979** *{published data only}*  
Hambleton G, Stone MJ. Comparison of IV salbutamol with IV aminophylline in the treatment of severe, acute asthma in childhood. *Archives of Disease in Childhood* 1979; **54**:391–402.
- Hayday 2002** *{published data only}*  
Hayday K, Stevermer JJ. In children hospitalized for asthma exacerbations, does adding ipratropium bromide to albuterol and corticosteroids improve outcome?. *Journal of Family Practice* 2002; Vol. 51, issue 3:280. [ : 0094–3509]
- Herman 1983** *{published data only}*  
Herman JJ, Noah ZL, Moody RR. Use of intravenous isoproterenol for status asthmaticus in children. *Critical Care Medicine* 1983;**11**:716–20.
- Hetzel 1976** *{published data only}*  
Hetzel MR, Clark TJH. Comparison of intravenous and aerosol salbutamol. *British Medical Journal* 1976;**2**(6014): 919.
- Hirsch 1979** *{published data only}*  
Hirsch SR. Intravenous therapy with terbutaline. *Chest* 1979;**75**:648.
- Hussein 1986** *{published data only}*  
Hussein A, von der Hardt H, Muller W, Schell SM. Intravenous infusion of reproterol in the treatment of acute severe asthma in children. *Monatsschrift fur Kinderheilkunde* 1986;**134**:192–6.
- Hussein 1986a** *{published data only}*  
Hussein A, von der Hardt H, Muller W, Schell SM. Intravenous infusion of reproterol a beta-2-mimetic agent in the therapy of severe asthma attacks in childhood. *Monatsschrift Kinderheilkunde* 1986; Vol. 134, issue 4: 192–6.
- Hutton 2002** *{published data only}*  
Hutton SF, Koval PG. Intravenous albuterol effective for acute severe asthma. *Journal of Family Practice* 2002; Vol. 51, issue 7:596. [ : 0094–3509]
- Iodice 1980** *{published data only}*  
Iodice F, Rufolo L, Piscione F, De Michele G. Hemodynamic and ventilatory effects of intravenous salbutamol in patients affected by cold. *Respiration* 1980;**40**:272–7.
- Janson 1988** *{published data only}*  
Janson C, Herala M, Sjogren I. Nebulization versus injection in ambulatory treatment of acute asthma: a comparative study. *British Journal of Diseases of the Chest* 1988; Vol. 82, issue 4:347–53.
- Janson 1992** *{published data only}*  
Janson C, Boman D. Intravenous theophylline after beta 2-agonist treatment in severe acute asthma. Effect on patients

- who are not pre-treated with theophylline. *Upsala Journal of Medical Sciences* 1992;**97**:149–55.
- Johnson 1978** *{published data only}*  
Johnson AJ, Spiro SG, Pidgeon J, Bateman S, Clarke SW. Intravenous infusion of salbutamol in severe acute asthma. *British Medical Journal* 1978;**1**:1013–5.
- Karetzky 1980** *{published data only}*  
Karetzky MS. Acute asthma: the use of subcutaneous epinephrine in therapy. *Annals of Allergy* 1980;**44**(1):12–4.
- Kornberg 1991** *{published data only}*  
Kornberg AE, Zuckerman S, Welliver JR, Mezzadri F, Aquino N. Effect of injected long-acting epinephrine in addition to aerosolized albuterol in the treatment of acute asthma in children. *Pediatric Emergency Care* 1991;**7** (1): 1–3.
- Lawford 1978** *{published data only}*  
Lawford P, Jones BJM, Milledge JS. Comparison of intravenous and nebulised salbutamol in initial treatment of severe asthma. *British Medical Journal* 1978;**1**:84.
- Lebovitz 2004** *{published data only}*  
Lebovitz DJ, Smith PG, O’Riordan M, Reed MD. Pharmacokinetic properties and tolerability of single-dose terbutaline in patients with severe asthma treated in the pediatric intensive care unit. *Current Therapeutic Research, Clinical & Experimental* 2004; Vol. 65, issue 1:98–109. [ 0011–393X]
- Li 2002** *{published data only}*  
Li YL, Luo YA, Wu YM. Comparison of relieving asthma effects of domestic and imported terbutaline injection. *Zhongguo Xinyao yu Linchuang Zazhi* 2002; Vol. 21, issue 2:97–9. [ 1007–7669]
- Lin 1996** *{published data only}*  
Lin YZ, Hsieh KH, Chang LF, Chu CY. Terbutaline nebulization and epinephrine injection in treating acute asthmatic children. *Pediatric Allergy & Immunology* 1996;**7** (2):95–9.
- Lowell 1987** *{published data only}*  
Lowell DI, Lister G, Von Koss H, McCarthy P. Wheezing in infants: the response to epinephrine. *Pediatrics* 1987;**79** (6):939–45.
- Marlin 1975** *{published data only}*  
Marlin G, Turner P. Intravenous treatment with rimeterol and salbutamol. *British Medical Journal* 1975;**2**:715–9.
- May 1975** *{published data only}*  
May CS, Paterson JW, Spiro SG, Johnson AJ. Intravenous infusion of salbutamol in the treatment of asthma. *British Journal of Clinical Pharmacology* 1975;**2**:503–8.
- Monie 1979** *{published data only}*  
Monie R, Evans WV. Saving asthmatics. *British Medical Journal* 1979; Vol. 2:334. [ 0007–1447]
- Naspitz 1987** *{published data only}*  
Naspitz CK, Sole D, Wandalsen N. Treatment of acute attacks of bronchial asthma. A comparative study of epinephrine subcutaneous and fenoterol inhalation. *Annals of Allergy* 1987;**59**(1):21–4.
- Ngamphaiboon 1989** *{published data only}*  
Ngamphaiboon J, Chumdermpadetsuk S. Nebulized salbutamol vs injected epinephrine in the treatment of acute asthma in children. *Chulalongkorn Medical Journal* 1989; **33**(9):669–73..
- Nograpy 1977** *{published data only}*  
Nograpy SG, Hartley JPR, Seaton A. Metabolic effects of intravenous salbutamol in the course of acute asthma. *Thorax* 1977;**32**:559–62.
- Noseda 1989** *{published data only}*  
Noseda A, Yernaut JC. Sympathomimetics in acute severe asthma: inhaled or parenteral, nebulizer or spacer?. *European Respiratory Journal* 1989;**2**:377–82.
- O’Connell 1990** *{published data only}*  
O’Connell MB, Iber C. Continuous intravenous terbutaline infusions for adult patients with status asthmaticus. *Annals of Allergy* 1990;**64**:213–8.
- Pang 1977** *{published data only}*  
Pang LM, Rodriguez-Martinez F, Davis WJ, Mellins RB. Terbutaline in the treatment of status asthmaticus. *Chest* 1977; Vol. 72, issue 4:469–73.
- Parry 1976** *{published data only}*  
Parry L, Martorano, Cotton E. Management of life-threatening asthma with intravenous isoproterenol infusions. *American Journal of Diseases of Children* 1976; **130**:39–42.
- Phanichyakarn 1989** *{published data only}*  
Phanichyakarn P, Kraisarin C, Sasisakulporn C. Comparison of inhaled terbutaline and terbutalife injection in treatment of acute asthmatic attacks in children. *Asian Pacific Journal of Allergy & Immunology* 1989; Vol. 7, issue 1:29–32.
- Pierce 1981** *{published data only}*  
Pierce RJ, Payne CR, Williams SJ, Denison DM, Clark TJH. Comparison of intravenous and inhaled terbutaline in the treatment of asthma. *Chest* 1981;**79**:506–11.
- Prego 2001** *{published data only}*  
Prego Petit J, Sehabiague Rigau GR, De Leonardis Capelo DJ, Pujadas Ferrer MA. Treatment of asthmatic crisis with intravenous salbutamol and in continuous nebulization in an emergency. *Archivos de Pediatra del Uruguay* 2001; Vol. 72:S5–S13.
- Quadrel 1995** *{published data only}*  
Quadrel M, Lavery RF, Jaker M, Atkin S, Tortella BJ, Cody RP. Prospective, randomized trial of epinephrine, metaproterenol, and both in the prehospital treatment of asthma in the adult patient. *Annals of Emergency Medicine* 1995;**26**(4):469–73.
- Quijada 1992** *{published data only}*  
Quijada C, Galleguillos F. Alternative treatment for acute asthmatic crisis. *Revista Médica de Chile* 1992; Vol. 120, issue 2:142–6.
- Rahman 1990** *{published data only}*  
Rahman M. Comparison of efficacy and safety of driphaler with nebular and injectable salbutamol in acute severe asthma. *Pakistan Journal of Medical Research* 1990;**29**(1): 29–35.

- Roberts 2003** *{published data only}*  
Roberts G, Newsom D, Gomez K, Raffles A, Saglani S, Begent J, et al. Intravenous salbutamol bolus compared with an aminophylline infusion in children with severe asthma: a randomised controlled trial. *Thorax* 2003; Vol. 58, issue 4:306–10. [0040–6376]
- Rodrigo 1994** *{published data only}*  
Rodrigo C, Rodrigo G. Treatment of acute asthma. Lack of therapeutic benefit and increase of the toxicity from aminophylline given in addition to high doses of salbutamol delivered by metered-dose inhaler with a spacer. *Chest* 1994; **106**(4):1071–6.
- Rossing 1980** *{published data only}*  
Rossing TH, Fanta CH, Goldstein DH, Snapper JR, McFadden ER, Jr. Emergency therapy of asthma: comparison of the acute effects of parenteral and inhaled sympathomimetics and infused aminophylline. *American Review of Respiratory Disease* 1980; **122**(3):365–71.
- Ruddy 1986** *{published data only}*  
Ruddy RM, Kolski G, Scarpa N, Wilmott R. Aerosolized metaproterenol compared to subcutaneous epinephrine in the emergency treatment of acute childhood asthma. *Pediatric Pulmonology* 1986; **2**(4):230–6.
- Salmeron 1988** *{published data only}*  
Salmeron S, Brochard L, Mal H, Tenaillon A, Henry-Amar M, Renon D, et al. Inhaled and intravenous salbutamol comparison in status asthmaticus. *Revue des Maladies Respiratoires* 1988; Vol. 5, issue Suppl 1:R124.
- Salmeron 1989** *{published data only}*  
Salmeron S, Brochard L, Mal H, Tenaillon A, Henry-Amar M, Renon D, et al. Inhaled and intravenous salbutamol in status asthmaticus?. *Revue des Maladies Respiratoires* 1989; Vol. 6, issue Suppl 2:R111.
- Salmeron 1994** *{published data only}*  
Salmeron S, Brochard L, Mal H, Tenaillon A, Henry-Amar M, Renon D, et al. Nebulized versus intravenous albuterol in hypercapnic acute asthma: A multicenter, double-blind, randomized study. *American Journal of Respiratory & Critical Care Medicine* 1994; **149**:1466–70.
- Salmeron 1995** *{published data only}*  
Salmeron S, Ellrodt A, Taravella O. Sympathomimetics in severe acute asthma. *Lancet* 1995; **346**:257.
- Schiavi 1987** *{published data only}*  
Schiavi E. Acute effect of intravenous salbutamol in status asthmaticus. Article in Spanish [Efecto agudo salbutamol intravenosos en et estado de mal asmatico]. *Medicina* 1987; **47**:39–44.
- Schwartz 1980** *{published data only}*  
Schwartz AL, Lipton JM, Warburton D, Johnson LB, Twarog FJ. Management of acute asthma in childhood. A randomized evaluation of beta-adrenergic agents. *American Journal of Diseases of Children* 1980; Vol. 134, issue 5: 474–8.
- Sharma 1984** *{published data only}*  
Sharma TN, Gupta RB, Gupta PR, Purohit SD. Comparison of intravenous aminophylline, salbutamol, and terbutaline in acute asthma. *Indian Journal of Chest Diseases & Allied Sciences* 1984; **26**:155–8.
- Smith 1986** *{published data only}*  
Smith SR, Kendall MJ. Potentiation of the adverse effects of intravenous terbutaline by oral theophylline. *British Journal of Clinical Pharmacology* 1986; **21**:451–3.
- Subias 1989** *{published data only}*  
Subias J, Manrique N, Hidalgo V. Status asthmaticus treatment: beta-agonist therapy experience in 71 cases. *Anales Espanoles de Pediatria* 1989; **31**:435–9.
- Swedish Society 1990** *{published data only}*  
Swedish Society of Chest Medicine, Janson C, Boe J, Boman G, Larsson S, Mossberg B, et al. High-dose inhaled versus intravenous salbutamol combined with theophylline in severe acute asthma. *European Respiratory Journal* 1990; **3**:163–70.
- Tarala 1981** *{published data only}*  
Tarala RA, Martyn V, Paterson JW. Effect of intravenous injection of rimiterol in asthma. *British Journal of Clinical Pharmacology* 1981; Vol. 12, issue 3:333–40.
- Teoh 1979** *{published data only}*  
Teoh P. Clinical evaluation of intravenous hexoprenaline in bronchial asthma. *Annals Academy of Medicine* 1979; **8**: 144–7.
- Thiringer 1976** *{published data only}*  
Thiringer G, Svedmyr N. Comparison of infused and inhaled terbutaline in patients with asthma. *Scandinavian Journal of Respiratory Diseases* 1976; **57**:17–24.
- Thompson 1977** *{published data only}*  
Thompson P, Friedman M. Intramuscular salbutamol in treatment of acute exacerbations of childhood asthma. *Archives of Disease in Childhood* 1977; Vol. 52, issue 7: 551–4.
- Ting 1991** *{published data only}*  
Ting C. A comparative study of epinephrine injection and beta-agonist inhalation in the treatment of childhood asthma. *Chung-Hua Min Kuo Hsiao Erh Ko i Hsueh Hui Tsa Chih* 1991; **32**:372–81.
- Tirot 1992** *{published data only}*  
Tirot P, Bouachour G, Varache N, Harry P, Bourrier P, Chenebault JM, et al. The use of intravenous adrenaline in acute severe asthma. *Revue des Maladies Respiratoires* 1992; **9**(3):319–23.
- Tribe 1976** *{published data only}*  
Tribe AE, Wong RM, Robinson JS. A controlled trial of intravenous salbutamol and aminophylline in acute asthma. *Medical Journal of Australia* 1976; **2**:749–52.
- Tripathi 1989** *{published data only}*  
Tripathi S. Management of acute bronchial asthma--intravenous terbutaline or aminophylline?. *Journal of the Indian Medical Association* 1989; **87**:75–6.
- Uden 1985** *{published data only}*  
Uden DL, Goetz DR, Kohen DP, Fifield GC. Comparison of nebulized terbutaline and subcutaneous epinephrine

- in the treatment of acute asthma. *Annals of Emergency Medicine* 1985;**14**(3):229–32.
- Van Renterghem 1987** *{published data only}*  
Van Renterghem D, Lamont H, Elinck W, Pauwels R, Van Der Straeten M. Intravenous versus nebulized terbutaline in patients with acute asthma: a double-blind study. *Annals of Allergy* 1987;**59**:313–6.
- Victoria 1989** *{published data only}*  
Victoria MS, Battista CJ, Nangia BS. Comparison between epinephrine and terbutaline injections in the acute management of asthma. *Journal of Asthma* 1989; Vol. 26, issue 5:287–90.
- Wheeler 2005** *{published data only}*  
Wheeler DS, Jacobs BR, Kenreigh CA, Bean JA, Hutson TK, Brilli RJ. Theophylline versus terbutaline in treating critically ill children with status asthmaticus: A prospective, randomized, controlled trial. *Pediatric Critical Care Medicine* 2005; Vol. 6, issue 2:142–7. [ : 1529–7535]
- Williams 1975** *{published data only}*  
Williams SJ, Parrish RW, Seaton A. Comparison of intravenous aminophylline and salbutamol in severe asthma. *British Medical Journal* 1975;**4**:685.
- Williams 1977** *{published data only}*  
Williams S, Seaton A. Intravenous or inhaled salbutamol in severe acute asthma?. *Thorax* 1977;**32**:555–8.
- Williams 1981** *{published data only}*  
Williams SJ, Winner SJ, Clark TJH. Comparison of inhaled and intravenous terbutaline in acute severe asthma. *British Medical Journal* 1975;**4**:685.
- Wood 1972** *{published data only}*  
Wood DW, Downes JJ, Scheinkopf H, Lecks HI. Intravenous isoproterenol in the management of respiratory arrest in childhood status asthmaticus. *Journal of Allergy & Clinical Immunology* 1972;**50**(2):75–81.
- Wood 1973** *{published data only}*  
Wood D, Downes J. Intravenous isoproterenol in the treatment of respiratory failure in childhood status asthmaticus. *Annals of Allergy* 1973;**31**:607–10.
- Zehner 1995** *{published data only}*  
Zehner WJ, Jr, Scott JM, Iannolo PM, Ungaro A, Terndrup TE. Terbutaline vs albuterol for out-of-hospital respiratory distress: randomized, double-blind trial. *Academic Emergency Medicine* 1995; Vol. 2, issue 8:686–91.
- Zhang 2004** *{published data only}*  
Zhang JX, Lin HQ, Chen JS. Clinical study on doxofylline injection in treatment of children with acute asthma attacks. *Zhonghua Erke Zazhi* 2004; Vol. 42, issue 2:143–4.
- Additional references**
- Beveridge 1996**  
Beveridge RC, Grunfeld AF, Hodder RV, Verbeek PR. Guidelines for the emergency management of asthma in adults. *Canadian Medical Association Journal (CMAJ)* 1996; **155**:25–37.
- Boulet 1999**  
Boulet L-P, Becker A, Berube D, Beveridge RC, Ernst P, on behalf of the Canadian Asthma Consensus Group. Canadian asthma consensus report. *CMAJ* 1999; **161**:(11 suppl).
- BTS 1997**  
The British Guidelines on Asthma Management: 1995 Review and Position Statement. *Thorax* 1997; Vol. 52: 153–6.
- BTS/SIGN 2011**  
British Guideline on the Management of Asthma. A national clinical guideline. British Thoracic Society [www.brit-thoracic.org.uk](http://www.brit-thoracic.org.uk) and Scottish Intercollegiate Guidelines Network [www.sign.ac.uk](http://www.sign.ac.uk) May 2008. Revised May 2011.
- Camargo 2011**  
Camargo Jr CA, Spooner C, Rowe BH. Continuous versus intermittent beta-agonists for acute asthma. *Cochrane Database of Systematic Reviews* 2011, Issue 4. [DOI: 10.1002/14651858.CD001115]
- Emerman 1999**  
Emerman CL, Woodruff PG, Cydulka RK, Gibbs MA, Pollack CV Jr, Camargo CA Jr. Prospective multicenter study of relapse following treatment for acute asthma among adults presenting to the emergency department.. *Chest* 1999 **115**:919–927.
- Emerman 2001**  
Emerman CL, Cydulka RK, Crain EF, Rowe BH, Radeos MS, Camargo CA Jr. Prospective multicenter study of relapse after treatment for acute asthma among children presenting to the emergency department.. *J Pediatrics* 2001 **138**:318–324.
- Ernst 1996**  
Ernst P, Fitzgerald J, Spier S. Canadian Asthma Consensus Conference: summary of recommendations. *Canadian Respiratory Journal* 1996;**3**:89–100.
- GINA 2011**  
GINA Report, Global Strategy for Asthma Management and Prevention. Global Initiative for Asthma (GINA). <http://www.ginasthma.org> December 2011.
- Higgins 2011**  
Higgins JPT, Green S, editors. *Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0*. The Cochrane Collaboration. Available from [www.cochrane-handbook.org](http://www.cochrane-handbook.org), 2011.
- Krishnan 2006**  
Krishnan V, Diette GB, Rand CS, Bilderback AL, Merriman B, Hansel NN, et al. Mortality in patients hospitalized for asthma exacerbations in the United States. *American Journal of Respiratory and Critical Care Medicine* 2006;**174** (6):633–8.
- Lipworth 1997**  
Lipworth BJ. Treatment of acute asthma. *Lancet* 1997;**350**: sii18–sii23.

**NAEPP 1997**

National Asthma Education Program Expert Panel Report  
2. Guidelines for the Diagnosis and Management of  
Asthma. Bethesda: NIH 1997:1.

**NHLBI/WHO 1995**

NHLBI/WHO Workshop Report. Global Initiative for  
Asthma: Global Strategy for Asthma Management and  
Prevention. Bethesda, MD: National Institutes of Health  
1985.

**NHS 2011**

NHS 2011 HES online hospital episode statistics.  
[www.hesonline.nhs.uk](http://www.hesonline.nhs.uk).

**NIH 2007**

NIH asthma guidelines, also known as Expert Panel Report  
3. <http://www.nhlbi.nih.gov/guidelines/asthma/>.

**Revman 2011**

The Nordic Cochrane Centre, The Cochrane Collaboration.  
Review Manager (RevMan). 5.1. Copenhagen: The Nordic  
Cochrane Centre, The Cochrane Collaboration, 2011.

**References to other published versions of this review****Travers 2001**

Travers AA, Jones AP, Kelly KD, Camargo CA Jr, Barker  
SJ, Rowe BH. Intravenous beta2-agonists for acute  
asthma in the emergency department. *Cochrane Database  
of Systematic Reviews* 2001, Issue 2. [DOI: 10.1002/  
14651858.CD002988]

\* *Indicates the major publication for the study*

## CHARACTERISTICS OF STUDIES

### Characteristics of included studies [ordered by study ID]

#### Bogie 2007

Methods	Prospective, randomised double blind, placebo-controlled trial	
Participants	46 paediatric patients with severe acute asthma who present to the emergency department	
Interventions	<p>IV terbutaline with nebulised albuterol, nebulised ipratropium and systemic corticosteroids versus IV placebo with nebulised albuterol, nebulised ipratropium and systemic corticosteroids. Details of dosage used is included below</p> <p>The independent variable (whether IV beta<sub>2</sub>-agonist or placebo) was initially given as loading dose of 10 mg/kg per minute over 10 to 20 minutes, and then as a continuous infusion of 1 mg/kg per minute. It was increased to 2 mg/kg per minute at the discretion of the attending physician or as a result of deteriorating CASS. If there was an additional decline in the participant's condition the dose was increased to 4 mg/kg per minute and aminophylline was also introduced</p> <p>The children in both arms of the study received continuous nebulized albuterol as follows 'at a dose determined by weight; 10 mg/h for children less than 20 kg, 15 mg/h for children between 20 and 40 kg, and 20 mg/h for children larger than 40 kg. For children less than 40 kg, the dose of albuterol could be increased every hour to a maximum of 20 mg/h. Ipratropium bromide nebulisation at 250 mg every 6 hours for children less than or equal to 10 kg and 500 mg every 6 hours for children equal to or greater than 11 kg was given to all study patients. Methylprednisolone was provided at a dose of 2 mg/kg loading dose followed by 1 mg/kg every 6 hours. All patients received a normal saline bolus of 20 mL/kg followed by maintenance intravenous fluids containing D5 1/2 NS with 20 mEq/L of KCl.'</p>	
Outcomes	<p>46 patients enrolled into study: 25 in IV terbutaline arm, and 21 in placebo arm</p> <p>Clinical Asthma Severity Score: mean improvement at 24 hours of 6.5 with IV terbutaline arm versus 4.8 with placebo arm (P = 0.073)</p> <p>Continuous nebulised albuterol duration of therapy: 38.19 hours in IV terbutaline arm versus 51.93 hours in placebo arm (P = 0.25)</p> <p>Pediatric Intensive Care Unit Length of Stay: mean 43.9 hours in IV terbutaline vs mean 56.85 hours in placebo arm (P = 0.345)</p>	
Notes	Contamination of IV terbutaline arm where discretion of the attending physician allowed titrating the study drug to 4ug/kg/min from baseline 2ug/kg/min. For this higher dose, aminophylline was added to the component therapy. 5/21 (24%) of placebo group received aminophylline, and 9/25 (36%) of terbutaline group received aminophylline	
<i>Risk of bias</i>		
<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>

**Bogie 2007** (Continued)

Random sequence generation (selection bias)	Low risk	Table of random numbers
Allocation concealment (selection bias)	Low risk	Concealed allocation
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double blind
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Double blind
Incomplete outcome data (attrition bias) All outcomes	Low risk	Of the 49 patients enrolled, 5 did not complete the study, but unclear which treatment arm
Selective reporting (reporting bias)	Unclear risk	No apparent indication of reporting bias

**Browne 1997**

Methods	<p>Randomisation: yes (table of random numbers)</p> <p>Blinding: double-blind</p> <p>Number excluded: 13</p> <p>Withdrawals: none</p> <p>Baseline characteristics: Heart rate 127.8 (15.4) intravenous + nebulised group (iv), 146.2 (13.6) nebulised group; Respiratory rate 38.9 (11.9) iv, 45.8 (9.9) nebulised; glucose 7.5 (2.7) iv, 8.5 (3.1) nebulised; potassium 3.9 (0.5) iv, 4.2 (0.6) nebulised; pulmonary index 12 iv, 15 nebulised; accessory muscle use 12 iv, 15 nebulised; Dyspnea 12 iv, 13 nebulised; wheeze 13 iv, 14 nebulised; fatigue 7 iv, 9 nebulised</p>
Participants	<p>Location: Westmead, Australia</p> <p>Participants: initially 50, 37 eligible, 29 final (8 gave no consent), 1-12 yrs (mean 8.4 iv, 6.3 nebulised); males 7 iv, 12 nebulised; females 7 iv, 3 nebulised; height 1.3m (0.2) iv, 1.2m (0.2) nebulised; weight 29.2 kg (10.1) iv, 22.5 kg (8.1) nebulised</p> <p>Asthma definition and severity: severe acute asthma as per National Australian Asthma Campaign guidelines</p> <p>Exclusion criteria: mild, moderate or life-threatening asthma, congenital heart disease,, family history or past episode of supraventricular tachycardia (SVT), respiratory illness, diabetes mellitus weighed &lt; 10kg or &gt; 50kg, aged &lt; 12months or &gt; 12yrs, or had already received the maximum iv dose for the day</p> <p>Inhaled corticosteroid use: no details</p>
Interventions	<p>Standard care: Coincident with iv drugs, O2 NPV 30%, continuous salbutamol 2.5 mg (&lt; 2 yrs ) or 5 mg ( &gt; 2 yrs ), hydrocortisone 5 mg/kg iv, then from 2 hrs onwards continuous salbutamol, then at 30 minutes, 60 minutes, 2 hours, 3 hours, 4 hours depending on clinical state</p> <p>Treatment group: salbutamol iv 15 ug/kg over 10 min at 0 min</p>

**Browne 1997** (Continued)

	Placebo: saline	
Outcomes	PFTs: not done Timing: not done Admissions: all patients admitted to high-dependency ward Side effects: higher proportion with tremor at 2 hours (specifics unknown) Complications:	
Notes	Run in period of 30 min where patients given salbutamol nebulised of 2.5 or 5 mg	
<b>Risk of bias</b>		
<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Random sequence generation (selection bias)	Low risk	Randomised by hospital pharmacy using a table of random numbers
Allocation concealment (selection bias)	Low risk	Investigators unaware as to order of randomisation sequence. Allocation sequence was retained by the pharmacy and released only when all clinical and laboratory assessments had been completed
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double-blind. Staff, investigators and patients were blinded and physicians who had administered the intravenous solution were surveyed to assess whether they had been aware of the solution being salbutamol or saline at the time of the bolus infusion and effective blinding was demonstrated
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Details of allocation released by pharmacy only when all clinical and laboratory assessments had been completed
Incomplete outcome data (attrition bias) All outcomes	Low risk	No patients withdrawn from trial
Selective reporting (reporting bias)	Unclear risk	No indication of reporting bias

**Nowak 2010**

Methods	Randomised, placebo-controlled, dose-escalation, multicentre trial
Participants	29 patients with severe acute asthma in emergency department setting
Interventions	All patients received nebulised albuterol and ipratropium with oral corticosteroids. Patients with FEV1 < 55% were randomised to MN-221 (bedoradrine) or placebo



**Nowak 2010** (Continued)

Outcomes	<p>13 patients received placebo and 16 patients received MN-221. MN-221 was administered at the following doses: 5 at 240 ug over 15 min, 6 at 450 ug over 15 min, and 5 at 1080 ug over two hours (2 received 1995 ug)</p> <p>Reduced hospitalisation rate: MN-221 4/16 (25%) vs placebo 7/13 (54%)</p> <p>Improved FEV1: change in baseline AUC1-5hr was 43% higher in the MN-221 arm compared to placebo</p> <p>No significant difference in adverse events between arms: ECG, heart rate, etc</p>	
Notes	Abstract format only.	
<b><i>Risk of bias</i></b>		
<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Random sequence generation (selection bias)	Unclear risk	Unclear. Conference abstract - limited information
Allocation concealment (selection bias)	Unclear risk	Unclear. Conference abstract - limited information
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Unclear. Conference abstract - limited information
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Unclear. Conference abstract - limited information
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Unclear. Conference abstract - limited information
Selective reporting (reporting bias)	Unclear risk	Unclear. Conference abstract - limited information

CASS: Clinical Asthma Severity Score  
 FEV1: forced expiratory volume in 1 sec  
 iv: intravenous  
 NPV: negative predictive value  
 PFTs: pulmonary function tests

### Characteristics of excluded studies [ordered by study ID]

Study	Reason for exclusion
Abd 1989	Epinephrine (rather than IV $\beta_2$ agonists).
Aggarwal 1986	Excluded on basis of non randomised clinical trial, unclear asthma severity of patients, and IV aminophylline versus IV epinephrine versus SC salbutamol
Anonymous 1978	Non-experimental study (not randomised controlled clinical trial)
Appel 1989	Epinephrine (rather than IV $\beta_2$ agonists).
Arnaud 1977	Not a randomised controlled clinical trial.
Arnaud 1982	D: RCT, (P): severe acute asthma, (I): IV terbutaline & steroids vs (C) IV steroids, (O): PEF Excluded on basis of comparing IV terbutaline & steroids vs IV steroids
Badatcheff 1989	D: Single blind RCT, (P): severe acute asthma, (I): IV salbutamol vs (C) IV EPI, (O): PEF Excluded on basis of comparing IV salbutamol vs IV EPI.
Baur 1988	D: non RCT, (P): severe acute asthma, (I): IV fenoterol vs (C) no comparator, (O): various outcomes including serum levels, PE, HR Excluded on basis of comparing IV fenoterol vs no comparator
Becker 1983	T: Epinephrine (rather than IV $\beta_2$ agonists).
Ben-Zvi 1980	D: RCT, (P): severe acute asthma, (I): SC EPI, SC sus-phrine salbutamol vs (C) nebulised fenoterol, (O): vitals, PEF Excluded on basis of comparing SC EPI vs SC sus-phrine salbutamol vs nebulised fenoterol
Ben-Zvi 1982	Epinephrine (rather than IV $\beta_2$ agonists).
Ben-Zvi 1983	Epinephrine (rather than IV $\beta_2$ agonists).
Beswick 1975	Not a randomised controlled clinical trial.
Bloomfield 1979	This trial does not compare the addition of iv $\beta_2$ -agonists to inhaled $\beta_2$ -agonists versus inhaled $\beta_2$ -agonists for acute asthma. The comparison was between salbutamol 5 mg IPPB at 0 min or at 60 min vs. salbutamol 500 ug iv over 3 minutes at 0 min or at 60 min
Blumenthal 1979	Letter, not a clinical trial.
Boe 1985	Not randomised controlled clinical trial. Intravenous beta-agonists use was not the primary research question (no control; compared 2 doses of terbutaline - dose response curve)
Bohn 1984	Not a randomised controlled clinical trial.
Brandstetter 1980	Epinephrine (rather than IV $\beta_2$ agonists).

(Continued)

Browne 2002	Excluded on basis of IV salbutamol with standard of care vs nebulised ipratropium with standard of care vs IV salbutamol and nebulised ipratropium vs standard of care
Bruguerolle 1991	Not a randomised controlled clinical trial.
Chanez 1990	Excluded on basis of IV terbutaline vs IV ANF.
Cheong 1988	This trial does not compare the addition of intravenous $\beta$ 2-agonists to inhaled $\beta$ 2-agonists versus inhaled $\beta$ 2-agonists for acute asthma. The comparison was between salbutamol 5 mg NEB at 30 min and at 120 min vs. salbutamol iv infusion 12.5 ug/min for four hrs at 30 min
Chiang 2000	Excluded on basis of no comparative cohort.
Claybo 1985	Excluded on basis of design: Letter to editor only, no data available
Crompton 1990	Review.
Davis 1977	Subcutaneous (rather than IV) $\beta$ 2 agonists.
Downes 1973	Not a randomised controlled clinical trial.
Edmunds 1981	Not a randomised controlled clinical trial.
Elenbaas 1985	Epinephrine (rather than IV $\beta$ 2 agonists).
Evans 1979	Exclude on basis of IV salbutamol vs. IV methylxanthines.
Evans 1980	Not a randomised controlled clinical trial - cohort study.
Fanta 1986	Epinephrine (rather than IV $\beta$ 2 agonists).
Femi-Pearse 1977	This trial does not compare the addition of intravenous $\beta$ 2-agonists to inhaled $\beta$ 2-agonists versus inhaled $\beta$ 2-agonists for acute asthma. The comparison was between i.v. salbutamol vs. i.v. aminophylline
Fitchett 1975	Not a randomised controlled clinical trial - cohort study.
Gotz 1981	Epinephrine (rather than IV $\beta$ 2 agonists).
Grant 1976	Letter to editor.
Greefhorst 1983	D: non RCT, (P): chronic stable asthma, (I): IV terbutaline vs (C) IV prenaterol, (O): PEF, vitals Excluded on basis of comparing IV terbutaline vs IV prenaterol
Greif 1985	Not a randomised controlled clinical trial - cohort study.
Hambleton 1979	This trial does not compare the addition of intravenous $\beta$ 2-agonists to inhaled $\beta$ 2-agonists versus inhaled $\beta$ 2-agonists for acute asthma. The comparison was between intravenous salbutamol vs. intravenous amino-

(Continued)

	phylline
Hayday 2002	D: Double blind RCT, (P): severe acute peds asthma, (I): nebulised ipratropium with standard care vs (C) standard care (nebulised albuterol and IV hydrocortisone), (O): PEF Excluded on basis of comparing nebulised ipratropium with standard care vs. standard care (NEB albuterol and IV hydrocortisone)
Herman 1983	Not a randomised controlled clinical trial - cohort study.
Hetzel 1976	Not a randomised controlled clinical trial - cohort study.
Hirsch 1979	Case report.
Hussein 1986	This trial does not compare the addition of intravenous $\beta_2$ -agonists to inhaled $\beta_2$ -agonists versus inhaled $\beta_2$ -agonists for acute asthma. The comparison was between IV reproterol vs. inhaled reproterol
Hussein 1986a	D: RCT, (P): severe acute asthma, (I): IV repoterol IV theoph, IV steroids vs (C) nebulised salbutamol, IV theoph, IV steroids EPI, (O): PEF Excluded on basis of comparing IV repoterol IV theophylline, IV steroids vs nebulised salbutamol, IV theophylline IV steroids EPI
Hutton 2002	D: RCT, (P): severe acute asthma, (I): IV salbutamol with standard care vs (C) nebulised ipratropium; vs (C2) IV salbutamol and nebulised ipratropium and standard care, (O): PEF Excluded on basis of comparing IV salbutamol with standard care vs (C) nebulised ipratropium; vs (C2) IV salbutamol and nebulised ipratropium and standard care
Iodice 1980	Not a randomised controlled clinical trial - cohort study.
Janson 1988	(D) Non-RCT, (P) stable asthmatics in outpatient setting, (I) terbutaline SC with amino IV, (C) terbutaline SC with delayed ipratropium nebulised, (C) terbutaline SC with concurrent ipratropium nebulised (C), (O) Exclude on basis of terbutaline SC with amino IV vs terbutaline SC with delayed ipratropium nebulised vs terbutaline SC with concurrent ipratropium nebulised
Janson 1992	Not a randomised controlled clinical trial.
Johnson 1978	This trial does not compare the addition of intravenous $\beta_2$ -agonists to inhaled $\beta_2$ -agonists versus inhaled $\beta_2$ -agonists for acute asthma. The comparison was between aminophylline infusion 1 mg/min at 75 min and 'control group' of inhaled salbutamol vs. salbutamol iv infusion at 10 ug/min at 75 min
Karetzky 1980	Epinephrine (rather than IV $\beta_2$ agonists).
Kornberg 1991	Epinephrine (rather than IV $\beta_2$ agonists).
Lawford 1978	This trial does not compare the addition of intravenous $\beta_2$ -agonists to inhaled $\beta_2$ -agonists versus inhaled $\beta_2$ -agonists for acute asthma. The comparison was between salbutamol 10 mg nebulised at 0 min lasting for 45 min vs. salbutamol iv infusion 20 ug/min at 0 min lasting for 45 min

(Continued)

Lebovitz 2004	Excluded on basis of design: (D) dose finding/pharmacokinetic study
Li 2002	D: RCT, (P): severe acute asthma, (I): IV terbutaline (domestic source); (C) IV terbutaline (local source), (O): PEF Excluded on basis of comparing IV terbutaline (domestic source) vs IV terbutaline (local source)
Lin 1996	Epinephrine (rather than IV $\beta_2$ agonists).
Lowell 1987	Epinephrine (rather than IV $\beta_2$ agonists).
Marlin 1975	Chronic asthma.
May 1975	Not a randomised controlled clinical trial - cohort study.
Monie 1979	Letter referring to a trial comparing aminophylline versus $\beta_2$ -agonists
Naspitz 1987	Epinephrine (rather than IV $\beta_2$ agonists).
Ngamphaiboon 1989	Epinephrine (rather than IV $\beta_2$ agonists).
Nogrady 1977	Case series.
Nosedá 1989	Review.
O'Connell 1990	Not a randomised controlled clinical trial - cohort study.
Pang 1977	Excluded on basis of design and no comparison group: (D) non RCT, (P) peds, (I) terbutaline SC, (C) nil
Parry 1976	Not a randomised controlled clinical trial - cohort study.
Phanichyakarn 1989	D: RCT, (P): severe acute asthma, (I): IV terbutaline vs (C) nebulised terbutaline, (O): PEF Excluded on basis of comparing IV terbutaline vs nebulised terbutaline
Pierce 1981	Patients were not seen in an emergency setting (study done in a lab setting)
Prego 2001	(D) non RCT, (P) peds severe asthma, (I) IV salbutamol, (C) NEB salbutamol, (O) various Excluded on basis of comparing IV salbutamol vs nebulised salbutamol
Quadrel 1995	Epinephrine (rather than IV $\beta_2$ agonists) study to be considered in separate Cochrane review
Quijada 1992	D: RCT, (P): severe acute asthma, (I): SC salbutamol vs (C) nebulised salbutamol, (O): PEF Excluded on basis of comparing SC salbutamol vs nebulised salbutamol
Rahman 1990	D: non RCT, (P): severe acute asthma, (I): SC salbutamol vs (C) 'nebuhaler', (O): PEF Excluded on basis of SC salbutamol vs 'nebuhaler'.
Roberts 2003	Intravenous salbutamol bolus compared with an aminophylline infusion

(Continued)

Rodrigo 1994	Addition of IV aminophylline to inhaled $\beta_2$ agonists. Study to be considered in separate Cochrane review
Rossing 1980	Epinephrine (rather than IV $\beta_2$ agonists).
Ruddy 1986	Epinephrine (rather than IV $\beta_2$ agonists).
Salmeron 1988	D: Double blind RCT, (P): severe acute asthma, (I): IV salbutamol vs (C) nebulised Salbutamol, (O): PEF Excluded on basis of comparing IV salbutamol vs nebulised Salbutamol
Salmeron 1989	D: Double blind RCT, (P): severe acute asthma, (I): IV salbutamol vs (C) nebulised Salbutamol, (O): PEF Excluded on basis of comparing IV salbutamol vs nebulised Salbutamol
Salmeron 1994	This trial does not compare the addition of intravenous $\beta_2$ -agonists to inhaled $\beta_2$ -agonists versus inhaled $\beta_2$ -agonists for acute asthma. The comparison was between albuterol 10 mg NEB (two 5 mg nebs over 15 min for one hour), then if successful continue Rx 5 mg nebulised q2h for 7 h vs. albuterol iv infusion of 8.3 ug/min for 60 min (total 500 ug) at 0 min lasting for 1 hr, then if successful continue Rx 500 ug/hr for 7h
Salmeron 1995	Letter to editor.
Schiavi 1987	Not a randomised controlled clinical trial.
Schwartz 1980	D: unknown RCT, (P): severe acute asthma, (I): SC EPI or terbutaline vs (C) nebulised isoetharine HCL, (O): PEF, various other Excluded on basis of comparing SC EPI or terbutaline vs nebulised isoetharine HCL
Sharma 1984	This trial does not compare the addition of intravenous $\beta_2$ -agonists to inhaled $\beta_2$ -agonists versus inhaled $\beta_2$ -agonists for acute asthma. The comparison was between intravenous salbutamol vs. iv aminophylline
Smith 1986	Non-experimental study (not randomised controlled clinical trial)
Subias 1989	Not a randomised controlled clinical trial.
Swedish Society 1990	This trial does not compare the addition of intravenous $\beta_2$ -agonists to inhaled $\beta_2$ -agonists versus inhaled $\beta_2$ -agonists for acute asthma. The comparison was between salbutamol 0.15 mg/kg nebulised at 0 min lasting 7 min, repeat x1 at 30 min (total nebulised = 0.30 mg/kg in 1 hour) vs. salbutamol 5 ug/kg iv over 10 min at 0 min
Tarala 1981	Excluded on basis of type of patients: stable adults in outpatient setting
Teoh 1979	Non emergency patients. Not randomised controlled clinical trial - cohort study
Thiringer 1976	Non-experimental study (not randomised controlled clinical trial). Patients were not seen in an emergency setting (study done in a lab setting)
Thompson 1977	Study on non-severe asthmatics in ambulatory setting.
Ting 1991	Not a randomised controlled clinical trial.

(Continued)

Tirot 1992	Not a randomised controlled clinical trial.
Tribe 1976	This trial does not compare the addition of intravenous $\beta$ 2-agonists to inhaled $\beta$ 2-agonists versus inhaled $\beta$ 2-agonists for acute asthma. The comparison was between theophylline 250 mg iv at 0 min over $\geq$ 5 min vs. salbutamol 100 ug iv at 0 min
Tripathi 1989	Not a randomised controlled clinical trial.
Uden 1985	Epinephrine (rather than IV $\beta$ 2 agonists).
Van Renterghem 1987	This trial does not compare the addition of intravenous $\beta$ 2-agonists to inhaled $\beta$ 2-agonists versus inhaled $\beta$ 2-agonists for acute asthma. The comparison was between terbutaline 0.1 mg/kg nebulised over 5 min at 0 min and 60 min vs. terbutaline 6 ug/kg iv over 5 min (q60min x1) at 0 min and 60 min
Victoria 1989	Trial compared subcutaneous epinephrine and terbutaline injections
Wheeler 2005	Comparing theophylline versus terbutaline.
Williams 1975	This trial does not compare the addition of intravenous $\beta$ 2-agonists to inhaled $\beta$ 2-agonists versus inhaled $\beta$ 2-agonists for acute asthma. The comparison was between aminophylline 500 ug iv at 0 min infused over 60 min vs. salbutamol 500 ug iv at 0 min infused over 60 min (8.33 ug/min)
Williams 1977	Non-experimental study (not randomised controlled clinical trial)
Williams 1981	This trial does not compare the addition of intravenous $\beta$ 2-agonists to inhaled $\beta$ 2-agonists versus inhaled $\beta$ 2-agonists for acute asthma. The comparison was between terbutaline 2.5 mg nebulised over 10 min (repeat X 2 for each time FEV1 maxed) vs. terbutaline 250 ug iv over 10 min at 0 min (repeat X 2 for each time FEV1 maxed)
Wood 1972	Not a randomised controlled clinical trial.
Wood 1973	Not a controlled clinical trial.
Zehner 1995	D: Double blind RCT, (P): severe acute asthma, (I): SC terbutaline vs (C) nebulised albuterol, (O): PEF Excluded on basis of comparing subcutaneous terbutaline vs nebulised albuterol
Zhang 2004	Not a randomised controlled clinical trial.

ANF: atrial natriuretic factor.

EPI: epinephrine

FEV1: forced expiratory volume in 1 sec

HR: heart rate

IPPB: intermittent positive-pressure breathing

iv: intravenous

NPV: negative predictive value

peds: paediatrics

PF: peak flow

PEF: peak expiratory flow  
PFTs: pulmonary function tests  
RCT: randomised controlled trial  
sc: subcutaneous  
vs: versus

**Study characteristics**

D: design  
P: participants  
I: interventions  
O: outcomes



## DATA AND ANALYSES

### Comparison 1. IV + inhaled beta agonist vs. inhaled beta-agonist

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Admissions	1		Odds Ratio (M-H, Fixed, 95% CI)	Totals not selected
2 Length of stay	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected
3 Pulse rate at 2 hours	1		Mean Difference (IV, Random, 95% CI)	Totals not selected
4 Clinical Failure	1		Peto Odds Ratio (Peto, Fixed, 95% CI)	Totals not selected

#### Analysis 1.1. Comparison 1 IV + inhaled beta agonist vs. inhaled beta-agonist, Outcome 1 Admissions.

Review: Addition of intravenous beta<sub>2</sub>-agonists to inhaled beta<sub>2</sub>-agonists for acute asthma

Comparison: 1 IV + inhaled beta agonist vs. inhaled beta-agonist

Outcome: 1 Admissions


Study or subgroup	IV + inhaled beta agonist	inhaled beta-agonist	Odds Ratio	
	n/N	n/N	M-H,Fixed,95% CI	M-H,Fixed,95% CI
Nowak 2010	4/16	7/13		0.29 [ 0.06, 1.38 ]

### Analysis 1.2. Comparison 1 IV + inhaled beta agonist vs. inhaled beta-agonist, Outcome 2 Length of stay.

Review: Addition of intravenous beta<sub>2</sub>-agonists to inhaled beta<sub>2</sub>-agonists for acute asthma

Comparison: 1 IV + inhaled beta agonist vs. inhaled beta-agonist

Outcome: 2 Length of stay




### Analysis 1.3. Comparison 1 IV + inhaled beta agonist vs. inhaled beta-agonist, Outcome 3 Pulse rate at 2 hours.

Review: Addition of intravenous beta<sub>2</sub>-agonists to inhaled beta<sub>2</sub>-agonists for acute asthma

Comparison: 1 IV + inhaled beta agonist vs. inhaled beta-agonist

Outcome: 3 Pulse rate at 2 hours



### Analysis 1.4. Comparison 1 IV + inhaled beta agonist vs. inhaled beta-agonist, Outcome 4 Clinical Failure.

Review: Addition of intravenous beta<sub>2</sub>-agonists to inhaled beta<sub>2</sub>-agonists for acute asthma

Comparison: 1 IV + inhaled beta agonist vs. inhaled beta-agonist

Outcome: 4 Clinical Failure

Study or subgroup	IV + inhaled beta agonist n/N	inhaled beta-agonist n/N	Peto Odds Ratio Peto,Fixed,95% CI	Peto Odds Ratio Peto,Fixed,95% CI
Browne 1997	5/14	14/15		0.09 [ 0.02, 0.38 ]

## APPENDICES

### Appendix 1. Sources and search methods for the Cochrane Airways Group Specialised Register (CAGR)

#### Electronic searches: core databases

Database	Frequency of search
CENTRAL ( <i>The Cochrane Library</i> )	Monthly
MEDLINE (Ovid)	Weekly
EMBASE (Ovid)	Weekly
PsycINFO (Ovid)	Monthly
CINAHL (EBSCO)	Monthly
AMED (EBSCO)	Monthly

#### Hand-searches: core respiratory conference abstracts

Conference	Years searched
American Academy of Allergy, Asthma and Immunology (AAAAI)	2001 onwards
American Thoracic Society (ATS)	2001 onwards
Asia Pacific Society of Respiriology (APSR)	2004 onwards
British Thoracic Society Winter Meeting (BTS)	2000 onwards
Chest Meeting	2003 onwards
European Respiratory Society (ERS)	1992, 1994, 2000 onwards
International Primary Care Respiratory Group Congress (IPCRG)	2002 onwards
Thoracic Society of Australia and New Zealand (TSANZ)	1999 onwards

### MEDLINE search strategy used to identify trials for the CAGR

#### Asthma search

1. exp Asthma/
2. asthma\$.mp.
3. (antiasthma\$ or anti-asthma\$).mp.
4. Respiratory Sounds/
5. wheez\$.mp.
6. Bronchial Spasm/
7. bronchospas\$.mp.
8. (bronch\$ adj3 spasm\$).mp.
9. bronchoconstrict\$.mp.
10. exp Bronchoconstriction/
11. (bronch\$ adj3 constrict\$).mp.
12. Bronchial Hyperreactivity/
13. Respiratory Hypersensitivity/
14. ((bronchial\$ or respiratory or airway\$ or lung\$) adj3 (hypersensitiv\$ or hyperreactiv\$ or allerg\$ or insufficiency)).mp.
15. ((dust or mite\$) adj3 (allerg\$ or hypersensitiv\$)).mp.
16. or/1-15

#### Filter to identify RCTs

1. exp "clinical trial [publication type]"/
2. (randomised or randomised).ab,ti.
3. placebo.ab,ti.
4. dt.fs.
5. randomly.ab,ti.
6. trial.ab,ti.

7. groups.ab.ti.
8. or/1-7
9. Animals/
10. Humans/
11. 9 not (9 and 10)
12. 8 not 11

The MEDLINE strategy and RCT filter are adapted to identify trials in other electronic databases.

## Appendix 2. Database search strategies

### Cochrane Airways Group Register of trials (CAGR)

(status\* or emergenc\* or ED or ER or trauma\* or emergent\* or casualty or observation\* or holding\* or admit\* or admission\* or discharg\* or hospitali\* or outpatient\* or acute\* or exacerbat\* or sever\*) AND (bronchodilat\* or “adrenergic beta-agonists” or beta-agonist or “beta agonist” or beta2\* or beta-2\* or albuterol or salbutamol or levalbuterol or levosalbutamol or ventolin\* or proventil or ventosol or proair or isoproterenol or metaproterenol or aluprent or terbutaline or brethine or bricanyl or fenoterol or bedoradrine or reproterol or clenbuterol ) AND ( intraven\* or IV or I.V. or bolus or infus\* or inject\*)

[This search was limited to records coded as 'asthma']

### Clinicaltrials.gov

search terms = intravenous

study type = interventional studies

conditions = asthma

## HISTORY

Review first published: Issue 12, 2012

## CONTRIBUTIONS OF AUTHORS

Travers A: Initiated the review, wrote the protocol, performed searches, performed quality assessments, entered data and performed analysis, and primary author of review. Jones AP: study selection, quality assessment, review of protocol; Camargo CA Jr: Protocol development, methodological input, statistical support, manuscript review at an early stage of this review's development; Rowe BH: Co-authored protocol, performed selection for inclusion and quality assessment, data extraction and data entry, manuscript review, conversion to RevMan at an early stage of this review's development, and as assigned editor for the Cochrane Airways Group. Milan SJ and Welsh E independently selected trials for inclusion from initial searches, and Travers A and Milan SJ independently selected trials for inclusion from full trial reports. Milan SJ and Travers A updated the 'Risk of bias' tables for trials already included in the review and similarly for any new trials identified in the update. Milan SJ entered data and this was verified by Cates C. Milan SJ drafted the review and further development was provided by Travers A and Cates C.

## **DECLARATIONS OF INTEREST**

None. The authors are not involved in the primary research reported in this systematic review and have not represented the producers of these agents in the past.

## **SOURCES OF SUPPORT**

### **Internal sources**

- University of Alberta, Faculty of Medicine & Dentistry, Canada.
- Alberta Heritage Foundation for Medical Research (AHFMR), Canada.
- NHS Research and Development, UK.
- National Institute for Health Research (SJM), UK.

### **External sources**

- Canadian Association of Emergency Physicians (CAEP), Canada.
- National Heart, Lung and Blood Institute (HL-03533 NIH; CA Camargo, Jr), USA.
- Canadian Institutes of Health Research (CIHR), Ottawa, ON (BH Rowe), Canada.